Navigation Links
DNA ends: Common tool, different job

Every time a cell repairs or replicates its DNA, the resulting single strand is wrapped up by a dedicated protein complex. In eukaryotes or organisms whose cells have a nucleus, this job is handled by a tripartite complex called replication protein A (RPA). Researchers at the Salk Institute for Biological Studies have now unearthed a novel RPA-like complex that specifically homes in on the short single-stranded DNA "tail" end of yeast chromosomes.

Their findings, reported in the online edition of Nature Structural & Molecular Biology, will help scientists to better understand the dynamics that keep chromosomes ends, called telomeres, intact.

"Identification of this new RPA-like complex, which is targeted to a specific region of the genome, suggests that multiple RPA-like complexes have evolved, each making individual contributions to genomic stability," says the study's lead author Vicki Lundblad, Ph.D., a professor in the Molecular Cell Biology Laboratory at the Salk Institute.

With each round of cell division, telomeres ?long stretches of repetitive DNA ?erode a little bit further. Some have likened this progressive shortening to a genetic biological clock that winds down over time. In fact, when telomeres reach a "critical length," the cell can no longer multiply ?a characteristic sign of cellular senescence.

In certain cells, such as our germ cells or baker's yeast cells, which need to divide indefinitely, an enzyme called telomerase elongates telomeres to compensate for the continual attrition at chromosome ends. At the same time, telomerase activity is the main mechanism by which human tumor cells achieve immortal growth.

In addition, the natural ends of chromosomes could potentially look like broken strands of DNA that a cell's repair machinery is designed to fix. This has been a long-standing puzzle, because mending chromosome ends as though they were double-strand breaks would result in either unregulated degradation or end-to-end fusions. Such repair events are lethal for the genome, and in certain settings, can promote the development of cancer.

About 10 years ago, Lundblad discovered that Cdc13, a protein that binds single-stranded telomeric DNA, plays a central role at the telomeres of baker's yeast. But the function of two Cdc13-associated proteins, Stn1 and Ten1, remained unclear.

When members of the Lundblad laboratory searched the Protein Data Bank for relatives of Stn1, they dug up Rpa2, the middle subunit of the RPA complex. In particular, Stn1 and Rpa2 share similarities in a region known as oligonucleotide/oligosaccharide-binding fold or OB-fold, a protein fold that is commonly used to recognize and bind to either DNA or RNA.

Based on these findings, Lundblad and her colleagues developed a model, which predicts that Cdc13, Stn1 and Ten1 come together at the very end of chromosomes to form a telomere-dedicated RPA-like complex they dubbed the t-RPA complex.

Graduate student and first author Hua Gao tested this model, using detailed biochemical experiments which revealed that Stn1 and Ten1 behave just like their counterparts in the conventional RPA complex. However, Stn1 and Ten1 have the same predilection for single-stranded telomeric DNA as Cdc13, thereby helping to ensure that this complex only targets chromosome tips.

According to Lundblad, this finding raises important questions about the potential biological parallels between the conventional RPA complex and the newly discovered t-RPA complex.

"Whereas the conventional RPA complex acts elsewhere in the genome to raise a red flag to attract the attention of the repair machinery," says Lundblad, "curiously, the t-RPA complex performs the exact opposite function at chromosome ends, ensuring that these tips do not become targets for DNA repair."


'"/>

Source:Salk Institute


Related biology news :

1. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
2. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
3. Men Estimate Mens Risks Of Common Disorders Higher Than Women Do, And Vice Versa
4. Use of Antibiotics for Acne May Increase Risk of Common Illness
5. Common viruses may cause cancer
6. Common alternative treatment for liver disease is found to be ineffective
7. Common molecular signature identified in solid tumors
8. Common bacteria pirate natural mechanism to get inside cells
9. Commonly used antidepressants may also affect human immune system
10. Common practices at petting zoos put visitors at risk
11. Common enzyme is a key player in DNA repair
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology: